ALLMedicine™ Androgenetic Alopecia Center

Jun 28th, 2022 - Many candidate genes for androgenetic alopecia (AGA) have been identified in studies of the Caucasians and some Asian populations. This study aimed to confirm the known susceptibility genes reported in previous studies and find additional candidat...

Jun 26th, 2022 - To observe the efficacy of unilateral subcutaneous injection of botulinum toxin A combined with finasteride and minoxidil in the treatment of androgenic alopecia. Thirty-seven patients with androgenic alopecia were treated with finasteride and min...

Jun 23rd, 2022 - A randomized, double-blind, Placebo-controlled, parallel group, dose escalation study to evaluate the safety, tolerability and pharmacokinetics (PK) of GT20029 following topical single ascending dose in healthy subjects and multiple ascending dose...

Jun 15th, 2022 - “No matter who the patient is, whether a child, adolescent, or adult, the key to figuring out hair disease is getting a good history,” Maria Hordinsky, MD, professor and chair of the department of dermatology at the University of Minnesota, Minnea.

May 29th, 2022 - Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was declared a pandemic by the World Health Organization, and COVID-19 continues to have a major impact on society. Numerous studies have re...

Jun 5th, 2018 - Male-pattern hair loss (MPHL, androgenetic alopecia) is a slowly progressive form of alopecia which begins after puberty. In 2010, we published the first Japanese edition of guidelines for the diagnosis and treatment of MPHL. It achieved the origi...

Nov 28th, 2012 - Androgenetic alopecia (AGA), or pattern hair loss, is a common disorder in both Asian men and women. There are several guidelines for the treatment of AGA which are suitable for Caucasian patients; however, each of these has some limitations. Furt...

Jun 23rd, 2022 - A randomized, double-blind, Placebo-controlled, parallel group, dose escalation study to evaluate the safety, tolerability and pharmacokinetics (PK) of GT20029 following topical single ascending dose in healthy subjects and multiple ascending dose...

May 25th, 2022 - A clinical trial to assess the effects and safety of PRP activated with pulsed electrical fields (PEFA-PRP) compared with unactivated PRP when used to treat AGA. The design of this small-scale, phase 1b/2a clinical trial is to demonstrate that pul...

May 18th, 2022 - To evaluate the safety and tolerability of TDM-105795 administered topically in healthy male subjects with androgenetic alopecia(AGA ). To evaluate the pharmacokinetics (PK)/Pharmacodynamics (PD) of TDM-105795 following administration of a single ...

May 11th, 2022 - Androgenetic alopecia may affect self-esteem and quality of life in several affected individuals. There are two FDA-approved drugs for pattern baldness: topical minoxidil and finasteride, both of which require at least a 4- to 6-month trial before...

May 9th, 2022 - Androgenetic alopecia (AGA) is a prevalent disease, occurring in 80% of Caucasian men and 50% of Caucasian women by age 701. Treatments for AGA are limited, and presently the only FDA-approved medications for AGA are topical minoxidil and oral fin...

Jun 15th, 2022 - “No matter who the patient is, whether a child, adolescent, or adult, the key to figuring out hair disease is getting a good history,” Maria Hordinsky, MD, professor and chair of the department of dermatology at the University of Minnesota, Minnea.

Feb 22nd, 2022 - Spironolactone was not associated with any meaningful increase in the risk of breast cancer or other solid organ cancers in a systematic review and meta-analysis covering seven observational studies and a total population of over 4. 5 million peopl.

Feb 10th, 2022 - In the treatment of male androgenetic alopecia (AGA), low-dose dutasteride (0.5 mg/d), used off label in the US, tops a ranking of the most commonly used oral and topical agents in a new meta-analysis. While up to 90% of men experience AGA in thei...

Feb 7th, 2022 - The 5-alpha reductase inhibitor (5-ARI) dutasteride (Avodart) likely is the most efficacious among the three drugs currently used to treat androgenetic alopecia (AGA), or male pattern baldness, according to a network meta-analysis. Overall rank fo...

Nov 4th, 2021 - Hair follicle miniaturization was a prominent feature of persistent chemotherapy-induced alopecia (pCIA) in breast cancer survivors who presented to four specialty hair clinics, and treatment with minoxidil (sometimes with antiandrogen therapy) wa...